Palladone Phased Launch Should Collect One Year Of Abuse Data, Cmte. Says
Executive Summary
The first phase of launch for Purdue's Palladone (hydromorphone) should collect data on abuse and diversion for a year, FDA's Anesthetic & Life Support Advisory Committee recommended Sept. 10
You may also be interested in...
Purdue Palladone Phased Launch To Begin In First Half 2005
Purdue is planning a phased launch of Palladone that includes an initial year and a half of detailing to pain specialists and other experienced opioid prescribers only, beginning in the first half of 2005
Purdue Palladone Phased Launch To Begin In First Half 2005
Purdue is planning a phased launch of Palladone that includes an initial year and a half of detailing to pain specialists and other experienced opioid prescribers only, beginning in the first half of 2005
Schedule II Drug Prescribing Would Require CME Under FDA, DEA Proposal
FDA and the Drug Enforcement Administration are encouraging legislation to require continuing medical education for renewal of DEA registration to prescribe Schedule II drugs